In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: Effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance

European Journal of Clinical Pharmacology

Volumn 67, Issue 8, 2011, Pages 815-824

  Wattanachai, Nitsupa ^a,b   Polasek, Thomas M ^b   Heath, Tahlia M ^b,c   Uchaipichat, Verawan ^d   Tassaneeyakul, Wongwiwat ^d   Tassaneeyakul, Wichittra ^a   Miners, John O ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d KHON KAEN UNIVERSITY   (Thailand)

Author keywords

"Albumin effect"; Cytochrome P450 2C8; In vitro in vivo extrapolation; Paclitaxel 6 hydroxylation; Paclitaxel clearance

Indexed keywords

BOVINE SERUM ALBUMIN; CYTOCHROME P450 2C8; PACLITAXEL;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CLEARANCE; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; COMPUTER SIMULATION; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; HYDROXYLATION; INDICATORS AND REAGENTS; KINETICS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; PACLITAXEL; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN, BOVINE; SOFTWARE; TISSUE BANKS;

EID: 79960952379     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1001-z     Document Type: Article

References (47)

1. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479
2. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171 (Pubitemid 27191615)
3. Miners JO,Mackenzie PI, Knights KM(2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:189-201
4. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359
5. Proctor NJ, Tucker GT, Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178 (Pubitemid 38299716)
6. Riley RJ, McGinnity DF, Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311
7. Ito K, Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112 (Pubitemid 40558152)
8. Miners JO, Knights KM, Houston JB, Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539
9. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Miners JO (2008) The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870-877 (Pubitemid 351574884)
10. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147 (Pubitemid 46456976)
11. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199 (Pubitemid 37518547)
12. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO (2010) In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther 334:609-618
13. Rowland A, Knights KM, Mackenzie PI, Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062 (Pubitemid 351717462)
14. Tang C, Lin Y, Rodrigues AD, Lin JH (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648-654 (Pubitemid 34579097)
15. Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A (2009) Prediction of drug clearance by glucuronidation fromin vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89
16. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439
17. Matsumoto S, Ding LR, Ishii M, Fischer NE, Inaba T (2002) The interaction of human and bovine serum proteins with CYP3A in human liver microsomes: inhibition of testosterone 6betahydroxylation by albumin, alpha-globulins, alpha(1)-acid glycoprotein and gamma-globulins. Toxicol Lett 136:33-41 (Pubitemid 35279616)
18. Xu BQ, Ishii M, Ding LR, Fischer NE, Inaba T (2003) Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci 72:1953-1962 (Pubitemid 36207532)
19. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062
20. Rifkind AB, Lee C, Chang TK, Waxman DJ (1995) Arachidonic acid metabolism by human cytochrome P450s 2 C8, 2 C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 320:380-389
21. Ferguson SS, Black K, Jackson JP (2008) The CYP2C subfamily. In: Ioannides C (ed) Cytochrome P450: role in the metabolism and toxicity of drugs and other xenobiotics. The Royal Society of Chemistry, Cambridge, p 206
22. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO (2004) Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2 C8 substrate selectivity and regioselectivity. Biochemistry 43:7834-7842 (Pubitemid 38787691)
23. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392 (Pubitemid 24053174)
24. Polasek TM, Elliot DJ, Lewis BC, Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996-1007 (Pubitemid 39612704)
25. Yamazaki H, Shimada T (1999) Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 29:231-241 (Pubitemid 29140093)
26. Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256-269 (Pubitemid 24315086)
27. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO (1994) Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776
28. Boye SL, Kerdpin O, Elliot DJ, Miners JO, Kelly L, McKinnon RA, Bhasker CR, Yoovathaworn K, Birkett DJ (2004) Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. Xenobiotica 34:49-60 (Pubitemid 38187062)
29. McLure JA, Miners JO, Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461 (Pubitemid 30229449)
30. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT (2004) Abundance of cytochromes P450 in human liver: a metaanalysis. Br J Clin Pharmacol 57:687-688
31. Walle T, Walle UK, Kumar GN, Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512
32. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330-335 (Pubitemid 29423714)
33. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457 (Pubitemid 29160110)
34. Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BJ, Houston JB (2006) Determination of a human hepatic scaling factor for predicting in vivo drug clearance. Pharmacol Res 23:533-539
35. Polasek TM, Polak S, Doogue MP, Rostami-Hodjegan A, Miners JO (2009) Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol 65:1203-1210
36. Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-14837
37. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF (2004) Structure of human microsomal cytochrome P450 2 C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497-9503 (Pubitemid 38296017)
38. Kumar GN, Walle UK, Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 268:1160-1165 (Pubitemid 24100328)
39. Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO (2000) The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 50:573-580 (Pubitemid 32010017)
40. Vaclavikova R, Horsky S, Simek P, Gut I (2003) Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 368:200-209 (Pubitemid 37255481)
41. Ludden LK, Ludden TM, Collins JM, Pentikis HS, Strong JM (1997) Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. J Pharmacol Exp Ther 282:391-396 (Pubitemid 27425566)
42. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11:8097-8104 (Pubitemid 41698753)
43. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW (2007) Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7:362-365 (Pubitemid 47484774)
44. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K (2010) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. doi:10.1038/tpj.2010.19
45. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C (2009) Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130-137
46. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223
47. Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data I: impact of inter-individual variability. Xenobiotica 36:473-497 (Pubitemid 43890728)